TMTPOST — Native AI Virtual Cell platform developer BioYao Technology Co., Ltd. finalized a strategic financing round of tens of millions of yuan on Friday to accelerate its biological data pipeline and model validation workflows. The capital injection was completed within a single week, underscoring intense institutional interest in the company’s proprietary artificial intelligence virtual cell (AIVC) simulation architecture. Financial mechanics indicate the fresh capital will be directly deployed to expand in-house wet-lab data collection capabilities and fund iterative research into novel computational biological models. By accelerating these technical verification timelines, the biotechnology startup aims to transition its simulated cellular frameworks from initial research phases to commercial, industrial-scale applications. Biotech platforms are aggressively scaling proprietary, high-fidelity biological datasets to overcome the chronic scarcity of high-quality training inputs that limits standard generative AI models in drug discovery. This rapid capital allocation enables BioYao to integrate its predictive cellular simulations into downstream pharmaceutical pipelines and corporate research networks. Establishing deep vertical partnerships across the clinical ecosystem creates a crucial data-loop moat that protects the startup's model accuracy against competing computational biology frameworks.